Video

Second-Line Therapy for Stage IV NSCLC

Second-line treatment recommendations for patients with stage IV non–small cell lung cancer who experience disease progression after immunotherapy.

Mark A. Socinski, MD: Before we move on, I want to go back to Neal. Essentially what we’ve done here is take what we used to do in the second line, which was immuno-monotherapy, and graft it on to standard first-line regimens. We combined first- and second-line standards in this setting. We’ve had a nice discussion about how successful that strategy was, but what do you do afterward? What do you do now in the second-line setting for these patients? The vast majority of patients are getting [chemotherapy/immunotherapy] combinations in the first-line setting. What do you do afterward?

Neal Edward Ready, MD, PhD: Thanks, Mark. Of course we’re trying to use clinical trials to figure out how to overcome immune resistance. When that’s not possible, for patients who have seen single-agent IO [immunotherapy], we’re going back to a platinum doublet, where patients who received chemotherapy/IO initially, we’re falling back on docetaxel, sadly. But I think that some of the progress we’ve made in KRAS, which you know KRAS tumors often do respond to immunotherapy, but they often eventually progress. The advent of targeted therapy for KRAS G12C gives us another option. Hopefully we’ll have more molecular therapies for some of these immune responsive tumors.

Mark A. Socinski, MD: It’s very nice after many years of not having a KRAS strategy, at least for a portion of the patients with KRAS [mutations], we do have a new option, which the recent data updated at ASCO [American Society of Clinical Oncology annual meeting] on the CodeBreaK 100 trial looked pretty promising. The only thing I would add is don’t forget about anti-VEGF in the second-line setting. I do use a lot of ramucirumab with docetaxel in this particular setting.

TRANSCRIPT EDITED FOR CLARITY

Related Videos
Dr Cascone on Evaluating Neoadjuvant Durvalumab-Based Regimens in Resectable NSCLC
FRCSI, FRCSEd, medical director, Thoracic Cancer Program, and associate executive director, AdventHealth Cancer Institute
Benjamin P. Levy, MD, clinical director, Medical Oncology, Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital; and associate professor, oncology, Johns Hopkins University School of Medicine
Russell Hales, MD, director, Thoracic Oncology Multidisciplinary Program, associate professor, clinical radiation oncology and molecular radiation sciences, and director, thoracic multidisciplinary clinic, John Hopkins University School of Medicine
Estelamari Rodriguez, MD, MPH, associate director, Community Outreach – Thoracic Oncology, Sylvester Comprehensive Cancer Center
Misty D. Shields, MD, PhD, assistant professor, clinical medicine, Department of Medicine, Division of Hematology/Oncology, Indiana University (IU) School of Medicine; and associate member, Experimental and Developmental Therapeutics, IU Melvin and Bren Simon Comprehensive Cancer Center
Corey J. Langer, MD, director, Thoracic Oncology, Penn Medicine; and professor, medicine (hematology-oncology), the Hospital of the University of Pennsylvania, Perelman School of Medicine
Alexander I. Spira MD, PhD, FACP, FASCO
Hidehito Horinouchi, MD, PhD